|

| 产地 | France |
| 品牌 | AntibodySystem |
| 货号 | YHC23101 |
| 用途 | 仅用于科研 |
| 包装规格 | 100 μg |
| 纯度 | 0.95% |
| CAS编号 | |
| 是否进口 | 否 |
| 货号 | YHC23101 |
| 产品名称 | Recombinant Human FABP1 Protein, N-His |
| 规格 | 100 μg |
| 价格 | 1880 |
| 状态 | Lyophilized |
| 储存缓冲液 | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| 纯度 | >90% as determined by SDS-PAGE. |
| 应用 | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| 内毒水平 | Please contact with the lab for this information. |
| 表达系统 | E. coli |
| Accession | P07148 |
| 蛋白长度 | Ser2-Ile127 |
| 预测分子量 | 16.39 kDa |
| 稳定性与储存条件 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 重悬 | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| 别名 | Fatty acid-binding protein, liver, FABP1, Fatty acid-binding protein 1, Liver-type fatty acid-binding protein, L-FABP, FABPL |
| 物种 | Homo sapiens (Human) |
| 运输 | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| 备注 | For research use only. |
背景介绍:
FABP1(肝脏脂肪酸结合蛋白1)主要富集于肝细胞胞质,负责转运脂肪酸,参与脂质摄取、代谢与储存。广泛存在于脂质代谢旺盛组织,功能异常会扰乱脂代谢平衡,是脂代谢方向研究的常用靶点。
Q1:这款重组人 FABP1 蛋白的纯度是多少?
A:本产品经 SDS-PAGE 检测,纯度大于 90%,可满足各类常规科研实验需求。
Q2:该 FABP1 蛋白如何复溶配制储备液?
A:可直接使用无菌水复溶配制储备液,详细标准化复溶操作步骤可查阅产品配套说明书。
Q3:这款重组 FABP1 蛋白的储存条件与保质期是什么?
A:日常频繁使用可保存于 2~8℃;长期保存需置于 - 20~-80℃环境,自收货之日起保质期 12 个月。储存需使用手动除霜冰箱,避免反复冻融,防止蛋白活性流失。
Q4:该重组人 FABP1 蛋白可应用于哪些实验?
A:产品适用于 ELISA、免疫原制备、SDS-PAGE、WB 等实验,目前生物活性检测正在推进中,仅可用于科研用途。
前沿相关研究:
1.Gut Dysbiosis Shaped by Cocoa Butter-Based Sucrose-Free HFD Leads to Steatohepatitis, and Insulin Resistance in Mice., PMID:38931284
2.The developmental pattern related to fatty acid uptake and oxidation in the yolk sac membrane and jejunum during embryogenesis in Muscovy duck., PMID:38943802
3.Identification of Differentially Expressed mRNAs and lncRNAs Contributes to Elucidation of Underlying Pathogenesis and Therapeutic Strategy of Recurrent Implantation Failure., PMID:38955937
4.An overview of circulating and urinary biomarkers capable of predicting the transition of acute kidney injury to chronic kidney disease., PMID:39007888
5.ELOVL5 and VLDLR synergistically affect n-3 PUFA deposition in eggs of different chicken breeds., PMID:39018654
6.Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors., PMID:39067439
7.Association of Initial and Changes in Serum A-FABP Level With the Development and Improvement of Presarcopenia., PMID:39097639